Corteva Agriscience (CTVA) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a beatable bar on Operating EBITDA given Q1 momentum and a better-than-feared H1, but the market will focus on whether management raises full-year guidance and how the Latin America CP volume ramp is tracking into H2; the biggest swing factor is the Q2 Crop Protection volume print and any guidance revision language.

Heading into Q2 2026, Corteva's setup is cautiously positive: consensus Operating EBITDA of ~$2.22B and Operating EPS of ~$2.25 represent a bar that management's own commentary suggests is achievable, given Q1 came in well above expectations and the first half was described as tracking "a little better than expected." Management's tone on the Q1 call was confident on controllables (productivity, royalty journey, tariff favorability) but deliberately cautious on back-half risks — oil price headwinds, Latin America acreage uncertainty, and CP pricing — which kept them from raising full-year guidance despite a substantial Q1 beat. Estimate revisions have been stable to modestly positive since the Q1 print, with FY2026 Operating EBITDA consensus sitting at ~$4.20B (at the top of the $4.0–$4.2B guidance range), suggesting the street is already pricing in a clean execution quarter. The stock has outperformed meaningfully since last earnings (+7.9% vs. S&P 500 +0.8% and MOO Agribusiness ETF –1.4%), reflecting both the Q1 beat and separation optionality (Vylor brand launch, Form 10 filing, September Investor Day catalyst), which means the stock is not cheap heading in. The key wildcard is whether FMC's confirmed Q2 guidance and improving Brazil order book (50%+ of H2 orders in hand by mid-June vs. 36% at Q1 earnings) translates into a similarly positive CP volume read-through for Corteva, and whether management finally upgrades full-year guidance — any guidance raise would be a meaningful positive catalyst given the stock's premium multiple.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a beatable but not low bar — Operating EBITDA of ~$2.22B implies ~+3% vs. Q2 2025 actuals, and the street is already near the top of guidance; the bigger swing factor is Crop Protection revenue, where volume growth must more than offset persistent low-single-digit pricing headwinds, and any upside surprise there would drive the most positive stock reaction.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. Q2 2026 consensus as of July 29, 2026. FY2026 guidance per Q1 2026 earnings call (May 5, 2026). Q1 2026 is the last reported quarter; Q2 2025 is the prior year comparable period.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Operating EBITDA & Operating EPS)

Operating EBITDA Beat/Miss History

Operating EPS Beat/Miss History

Pattern: CTVA has beaten Operating EBITDA consensus in 6 of the last 8 quarters and Operating EPS in 7 of the last 8 quarters, with the beats concentrated in Q1 and Q2 (the seasonally heavy seed quarters); the two misses (Q3 2024 EBITDA and Q3 2024 EPS) both occurred in the seasonally weakest quarter, suggesting the bar is consistently set too low in peak quarters.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year guidance has been reaffirmed but not raised since the Q1 print despite a strong beat — management's deliberate caution on back-half risks (oil prices, Latin America acreage, CP pricing) is the key tension heading into Q2; any guidance raise at this print would be a meaningful positive catalyst, while a second consecutive reaffirmation would likely be viewed as neutral-to-slightly-disappointing given the stock's premium.

Source: CTVA Q1 2026 Earnings Call Transcript (May 5–6, 2026); CTVA 8-K/A filed June 12, 2026; Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — FY2026 Operating EBITDA consensus has barely moved (+0.2%) and Q2 2026 estimates are essentially flat, suggesting the street is waiting for Q2 results before making a directional call; the key tension is that consensus FY2026 Operating EPS ($3.78) is already above the top of guidance ($3.70), meaning the street is implicitly pricing in a guidance raise — if management reaffirms again without raising, estimates may drift lower.

Estimates have been essentially flat since the Q1 print, with the most notable tension being FY2026 Operating EPS consensus ($3.78) sitting 5.8% above the top of management's guidance range ($3.70) — the street is implicitly pricing in a guidance raise. If Q2 delivers another beat and management raises the EPS range, the consensus-to-guidance gap closes constructively; if guidance is reaffirmed again, estimates may need to come down modestly.

Source: Visible Alpha Consensus and Actuals Data. Post-Q1 baseline as of May 12, 2026 (5 trading days after May 5, 2026 earnings).

5. Stock Performance

Key Takeaway: CTVA has significantly outperformed both the S&P 500 (+7.9% vs. +0.8%) and the MOO Agribusiness ETF (+7.9% vs. −1.4%) since the Q1 earnings print on May 5, 2026, driven by a combination of the Q1 beat, separation execution milestones (Vylor brand, Form 10 filing, September Investor Day catalyst), and the royalty-positive upgrade — the outperformance is multiple-driven rather than estimate-driven, which raises the bar for Q2 to sustain the premium.

CTVA vs. MOO (VanEck Agribusiness ETF) vs. S&P 500 (SPY) — Indexed to 100 at May 5, 2026 (Last Earnings Date). Source: Stock Price Data.

• CTVA: $83.90 → $90.51 (+7.9%) since May 5, 2026 earnings date (as of July 30, 2026 close)
• S&P 500 (SPY): $723.77 → $729.46 (+0.8%) over the same period
• MOO (VanEck Agribusiness ETF): $84.56 → $83.39 (−1.4%) over the same period — CTVA outperformed its ag peer group by ~930 bps
• Key events marked: June 12 — 8-K/A filing raising CP restructuring charges by $100–$115M and announcing Spain site closure (stock dipped briefly then recovered); June 29 — Vylor board announced and Form 10 publicly filed (stock rallied, separation execution de-risked)
• Sector ETF: MOO (VanEck Agribusiness ETF) used as the sector benchmark — appropriate for CTVA's agricultural inputs sub-sector

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the formal filing of the Vylor Form 10 and board announcement on June 29, which de-risks the Q4 2026 separation timeline and sets up the September 15 Investor Day as the next major catalyst; the CP restructuring charge increase (June 12) is a modest negative but non-cash and consistent with the long-term footprint optimization story.

• June 29, 2026 — Vylor Form 10 Publicly Filed & Board Announced (8-K): Corteva filed the public Form 10 for Vylor (the future seed/genetics company) and announced the nine-person board of directors for the new standalone Crop Protection company, with Greg Page (retired Cargill Chairman/CEO) as Independent Chair. Separation remains on track for Q4 2026. Implication: Execution de-risked; September 15 Investor Day (two separate days, one per company) is the next major catalyst with 2029 outlooks and capital deployment strategy to be disclosed.
• June 12, 2026 — 8-K/A: CP Restructuring Charges Raised $100–$115M; Spain Site Closure: Corteva raised aggregate pre-tax restructuring charges to $750M–$815M (from prior ~$650–$700M), adding the intended cessation of production at its Asturias, Spain site and revising Pittsburg, CA exit estimates. Cash payments of $400M–$443M expected; actions substantially complete by end of 2028. Implication: Modestly negative on near-term cash flow but consistent with the long-term CP footprint optimization and cost savings story; $300M total run-rate productivity target by 2027 remains intact.
• June 17, 2026 — EU Parliament Approves New Genomic Techniques (NGT) Regulation: The EU Parliament voted to approve the NGT framework, enabling cultivation of gene-edited crops in Europe for the first time after a 30+ year GMO ban. Full implementation expected ~mid-2028. Implication: Significant long-term positive for Vylor; Corteva's strong European seed footprint (corn, oilseed rape) positions it to benefit directly; first gene-edited commercial corn hybrid targeted for 2028 launch.
• June 10, 2026 — Corteva Participates in Wolfe Materials of the Future Conference: Management presented at the Wolfe conference alongside FMC and other ag/materials peers. No material guidance changes disclosed. Implication: Consistent with separation execution messaging; FMC's concurrent appearance (confirming Q2 guidance) is a positive read-through for CP demand.
• May 21, 2026 — Q2 2026 Earnings Date Announced: Corteva confirmed Q2 2026 results will be released July 30, 2026 (after market close) with a conference call on July 31, 2026 at 9:00 AM ET.
• May 5, 2026 — Q1 2026 Earnings Beat; Full-Year Guidance Reaffirmed: Operating EPS of $1.50 beat consensus of $1.18 by $0.32 (+27%); revenue of $4.905B beat consensus; Operating EBITDA of $1.438B beat consensus of $1.264B by +13.8%. Full-year guidance reaffirmed at $4.0–$4.2B EBITDA and $3.45–$3.70 EPS. Royalty status upgraded to royalty positive for 2026 (ahead of prior neutral target). Implication: Strong beat but guidance reaffirmation (not raise) was the key disappointment; stock reaction was modestly positive as much of the beat was anticipated.
• Analyst Price Target Changes (Post-Q1): Deutsche Bank raised PT to $100 (May 11); Wells Fargo raised PT to $90 with Overweight (April 21); Barclays raised PT to $91 with Overweight (June 11); RBC raised PT to $103 with Outperform (late July); Berenberg raised PT to $78 with Hold (March 26). Consensus rating: Moderate Buy; average PT ~$89.90–$90.70. Implication: Broad-based PT upgrades post-Q1 reflect confidence in the separation story and EBITDA trajectory; stock is now trading near the average PT, limiting near-term upside unless guidance is raised.

7. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer commentary since CTVA's Q1 earnings (May 5, 2026) is broadly constructive for CTVA's Q2 print: FMC explicitly confirmed Q2 guidance and highlighted a dramatically improved Brazil order book (50%+ of H2 orders in hand by mid-June vs. 36% at Q1 earnings), which is a direct positive read-through for CTVA's CP Latin America volume; Nutrien flagged healthy crop input demand and clean channel inventory heading into summer; Mosaic highlighted Brazil fertilizer supply constraints that could pressure corn acreage (a modest negative for CTVA Seed) but also noted that underapplication of nutrients historically drives demand normalization; Scotts Miracle-Gro (consumer ag) confirmed full-year guidance with slightly elevated retailer inventories but no structural demand concern.

FMC Corporation — BMO Farm to Market Conference (May 14, 2026) & Wolfe Materials of the Future Conference (June 17, 2026)

Relevance to CTVA: FMC is CTVA's closest pure-play Crop Protection peer and a direct read-through on CP pricing, Latin America/Brazil demand, and channel dynamics heading into Q2 and H2 2026.

• Brazil order book dramatically improved: At the BMO conference (May 14), FMC CEO Pierre Brondeau disclosed that direct sales orders for H2 had jumped from 36% (at Q1 earnings) to 50% in just two weeks, with a target of 65–70% of H2 direct sales in hand by end of June. By the Wolfe conference (June 17), Brondeau confirmed the order book was "at the upper end of the historical range, double of last year." CTVA read-through: Strongly positive for CTVA's CP Latin America volume in H2 2026, which management flagged as the key driver of back-half CP momentum. If FMC's Brazil order book is at historical highs, CTVA's CP volume guidance for H2 is likely achievable.
• CP pricing stabilizing but not yet recovering: FMC noted that generic pricing pressure is "leveling off" and pricing is no longer in a "constant spiral down." Export statistics from China and India show generic prices doubling in some cases, but FMC is "not yet seeing it on the market." Europe price increases are holding. Latin America showing "indications of stabilization" primarily on non-selective herbicides (glyphosate, 2,4-D) rather than selective herbicides. CTVA read-through: Consistent with CTVA's own guidance of low-single-digit CP pricing headwinds persisting through year-end; no upside surprise on pricing expected in Q2, but the stabilization narrative supports the H2 recovery thesis management has been telegraphing.
• Q2 guidance confirmed: At the Wolfe conference (June 17), Brondeau stated "I think the quarter is good" and "I can confirm guidance for Q2" — a rare explicit intra-quarter confirmation. Full-year guidance also unchanged. CTVA read-through: Positive signal that the CP market environment in Q2 is tracking to plan; reduces downside risk for CTVA's Q2 CP segment.
• Strategic optionality: FMC disclosed it expects a strategic decision (sale, merger, or standalone plan) by the Q2 earnings call (end of July). FMC also highlighted four new molecules launching 2025–2028, including one licensed to Corteva, representing over $2B in sales. CTVA read-through: The Corteva-licensed FMC molecule (referenced as contributing to FMC's $300–$400M new product revenue in 2026) is a positive for CTVA's new product pipeline and CP differentiation story.
• Credit discipline in Brazil: FMC is selling only on cash terms to two PE-backed roll-ups that went into financial restructuring, and shifting mix toward co-ops and direct-to-farmer. CTVA read-through: Consistent with CTVA's own barter program and credit management approach in Brazil; bad debt risk appears manageable for both companies.

Nutrien Ltd. (NTR) — Q1 2026 Earnings Call (May 7, 2026)

Relevance to CTVA: Nutrien is the world's largest crop nutrient company and a key read-through on North American and Brazilian farm economics, crop input demand, and channel inventory heading into the planting season.

• Healthy crop input demand in core markets: Nutrien reported "healthy crop input demand over the first 4 months of 2026" with increased demand across core geographies (U.S. and Australia). Management characterized spring as "an active normal spring" with strong grower engagement. CTVA read-through: Positive for CTVA's North America Seed and CP volumes in Q2; farmers focused on maximizing yields after a large 2025 crop extracted significant nutrients from soil.
• Channel inventory clean heading into summer: Nutrien expects both its own distribution network and wholesale customers to be "very empty" as spring ends, with no concerns about containment or product backing up. CTVA read-through: Positive for CTVA's CP channel dynamics; clean inventory reduces the risk of destocking headwinds in H2 2026.
• Corn and soybean acreage stable: Nutrien maintained its acreage estimates of 94–96M acres of corn and 84–86M acres of soybeans, with no significant farmer switching observed. CTVA read-through: Broadly consistent with CTVA's own guidance of 3–4% corn acre reduction (corn-to-soy shift); no incremental negative surprise on acreage.
• Brazil: multiyear low inventories, but credit and access headwinds: Potash inventories in Brazil were at multiyear lows at the start of the year. However, farmer economics and access to credit remain "significant headwinds" and availability of nutrients and raw materials is weighing on Brazilian agriculture. Nutrien is reviewing its Brazilian retail operations and has commenced a sale process for its Brazilian soybean seed business. CTVA read-through: Mixed — low inventory is positive for restocking demand, but credit and input cost headwinds could pressure farmer purchasing decisions for CP products in H2. Nutrien's exit from Brazilian soybean seed could create market share opportunity for Vylor.
• Middle East conflict / nitrogen supply shock: Nutrien flagged the Iran conflict as a "huge supply shock" for nitrogen and phosphate, with elevated prices potentially persisting into 2027. Fuel and freight costs are also elevated. CTVA read-through: Consistent with CTVA's $40M oil price headwind already included in guidance; higher fertilizer costs at the farm level could pressure Latin America corn acreage (a risk CTVA management flagged on the Q1 call).
• Full-year guidance unchanged; feeling better than start of year: Nutrien maintained full-year retail EBITDA guidance of $1.75–$1.95B and stated management is "feeling better than at the start of the year." CTVA read-through: Positive sentiment signal for the broader ag input market; Nutrien's confidence in its retail business (which sells CTVA products) is a constructive backdrop.

Mosaic Company (MOS) — Q1 2026 Earnings Call (May 11, 2026)

Relevance to CTVA: Mosaic is a key read-through on Brazil farm economics, fertilizer availability, and Latin America acreage decisions — all of which directly affect CTVA's H2 CP volume and Seed demand in Brazil.

• Brazil fertilizer supply critically constrained: Mosaic disclosed that Brazil imports 85% of its NPK needs, and in-country inventory is "extremely low for all nutrients." Nitrogen and phosphate shipments are unlikely to catch up given low international availability. Management stated bluntly: "2026 is likely going to be a contraction in fertilizer use in Brazil just due to the sheer fact that nutrient availability is not there." CTVA read-through: Negative for CTVA's Brazil Seed segment — fertilizer scarcity could pressure safrinha corn acreage (already expected to be flat per CTVA's Q1 call) and potentially reduce soybean area. This is the most significant negative read-through from peers for CTVA's Q2 and H2 outlook.
• Farm economics challenging; phosphate margins under pressure: Global phosphate prices are putting "additional pressure on farm economics." Mosaic is curtailing production at Bartow and Louisiana (about half capacity each) and idling Brazil operations due to unsustainable stripping margins from elevated sulfur and ammonia costs. CTVA read-through: Elevated input costs at the farm level are a headwind for farmer purchasing power, which could modestly pressure CP product demand in Brazil in H2 2026.
• Underapplication of fertilizer creates future demand normalization: Mosaic management noted that persistent underapplication of phosphate "has historically been an important driver of demand normalization as growers respond" and that "ag commodity prices [are] actually being pressured in a good way on the upside, where affordability concerns will get better for farmers in time." CTVA read-through: Longer-term positive — yield pressure from underapplication could drive higher crop prices and improved farmer economics in 2027, supporting CTVA's H2 2026 and 2027 CP volume recovery thesis.
• Mosaic Biosciences (biologicals) growing rapidly: Mosaic Biosciences revenues expected to "double again in 2026" with 8–10 new product launches, "despite the financial pressure on farmers." CTVA read-through: Positive read-through for CTVA's biologicals portfolio (Utrisha, BlueN), which management has flagged as a key H2 CP growth driver; strong biologicals demand is a sector-wide trend.
• CapEx cut $250M; workforce reduction: Mosaic lowered 2026 CapEx guidance by $250M to $1.25B and initiated a workforce reduction expected to generate $50M in annualized savings. CTVA read-through: Neutral for CTVA directly; signals broader ag sector cost discipline in a challenging environment.

Scotts Miracle-Gro (SMG) — Q3 FY2026 Earnings Call (July 29, 2026)

Relevance to CTVA: SMG is a consumer-facing ag/lawn & garden company — a more distant read-through, but relevant for herbicide/pesticide demand trends, channel inventory dynamics, and commodity cost pressures heading into H2 2026.

• Full-year guidance raised; EPS upgraded: SMG raised FY2026 non-GAAP adjusted EPS guidance to $4.30–$4.45 (from prior range). U.S. consumer sales growth expected at the lower end of low-single-digit guidance due to slightly elevated retailer inventories entering Q4. CTVA read-through: Broadly positive — SMG's guidance raise signals the consumer ag market is holding up despite macro headwinds; elevated retailer inventories are a Q4 issue for SMG but not a structural demand problem.
• Pest control demand strong; Ortho herbicide outperforming: 82% of consumers consider pest control a necessity; Ortho control products up 15% YTD; Ortho Roundup (herbicide) was one of the strongest POS performers. CTVA read-through: Positive for herbicide/pesticide demand broadly; consumer willingness to spend on crop protection products is a constructive backdrop.
• Commodity costs up $15M vs. plan; mostly locked for rest of year: SMG expects a $15M increase in commodity costs above initial plan for FY2026, with most recognized in Q3. However, "nearly all of our cost of goods are locked" for the remainder of the fiscal year. Diesel and freight costs are elevated. CTVA read-through: Consistent with CTVA's own oil price headwind narrative; input cost pressures are real but manageable and largely locked in for 2026.
• Retailer inventories slightly elevated: Retailer inventories were "slightly elevated over prior year by high single digit percentages" entering Q4, partly due to weather softness in early May. Management is working with customers to reduce inventories and does not see it as a "massive impediment" to FY2027 growth. CTVA read-through: Modest negative for consumer-facing CP products; less relevant for CTVA's professional/agricultural CP segment, which operates through different channels.
• FY2027 outlook constructive: SMG expects a "rebound towards the algorithm" of 3% sales growth in FY2027, with gross margin expansion driven by pricing, cost-out, and innovation. CTVA read-through: Positive for the broader ag input sector recovery narrative into 2027, consistent with CTVA's own H2 2026 and 2027 CP pricing recovery thesis.

Peer Commentary Summary Table

8. Insider Transaction Activity

Key Takeaway: The only insider transaction since the Q1 earnings print is a stock award (Form 4 code “A”) to Luke Kissam (incoming CEO of the new Crop Protection company) upon joining on June 1, 2026 — this is a compensation grant, not an open-market purchase or sale, and carries no directional signal; there are no open-market buys or sells by insiders in the period, which is notable but not unusual given the company is in a quiet period ahead of a major corporate event (separation).

No open-market buys (Form 4 code P) or open-market sells (Form 4 code S) were recorded for CTVA insiders in the period from May 5, 2026 (Q1 earnings) through July 29, 2026. The absence of insider selling ahead of a major corporate event (separation) and into a period of strong stock outperformance is a mild positive signal — insiders are not taking profits despite the stock's +7.9% gain since Q1 earnings.

Source: SEC Form 4 filings / Insider Transaction Data.